Tags : Non-Cystic Fibrosis Bronchiectasis

Regulatory

Insmed’s Brensocatib Receives the US FDA’s Breakthrough Therapy Designation to

Shots: The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21 Brensocatib is a novel oral, reversible DPP1 inhibitor, currently being developed for the treatment of bronchiectasis and other inflammatory diseases Click […]Read More